Showing 5681-5690 of 8206 results for "".
- American Academy of Dermatology Issues Updated Guidelines for the Management of Acnehttps://practicaldermatology.com/news/american-academy-of-dermatology-issues-updated-guidelines-for-the-management-of-acne/2462235/Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty. Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. To help ensure that
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals
- Skin Cancer Combination Therapy Linked with Reduced Recurrence, Death: Studyhttps://practicaldermatology.com/news/merck-moderna-detail-potential-skin-cancer-vaccine-progress/2462183/Merck and Moderna
- Mathematical Dermatology: The Dawn of a New Multidisciplinary Research Fieldhttps://practicaldermatology.com/news/mathematical-dermatology-research-on-csu-may-sire-a-new-specialty/2462167/Chronic spontaneous urticaria (CSU) has a clear and visible appearance on the skin surface, but the mechanism underlying the various shapes of wheals in vivo remains largely obscured. To address this, a research group led by Professor Sungrim Seirin-Lee at Kyoto University Institu
- Biosimilar News: Samsung Bioepis Secures US License Date for Proposed Stelara Biosimilarhttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-secures-us-license-date-for-proposed-stelara-biosimilar/2462165/Samsung Bioepis Co., Ltd. signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara&nb
- New Deadline: Allergan Aesthetics, University Lab Partners Launch Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://practicaldermatology.com/news/news-you-can-use-allergan-aesthetics-university-lab-partners-launch-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups/2462091/University Lab Partners (ULP) and Allergan Aesthetics are launching the Golden Passport pitch competition for aesthetic startups. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including scientific and business lea
- Unmet Needs in Dermatology: NFX-179 Topical Gel May Shrink Cutaneous Neurofibromas in NF1 Patientshttps://practicaldermatology.com/news/unmet-needs-in-dermatology-nfx-179-topical-gel-may-shrink-cutaneous-neurofibromas-in-nf1-patients/2462134/NFX‑179 Gel produced a statistically significant improvement over vehicle in the shrinkage of cutaneous neurofibromas in people with neurofibromatosis type 1 (NF1), according to positive topline results from a Phase 2b clinical trial. Cutaneous neurofibromas (cNFs) appear in over 9
- Tralokinumab Shows Improvements in Dupilumab Patients Up to 52 Weekshttps://practicaldermatology.com/news/tralokinumab-shows-improvements-in-dupilumab-patients-up-to-52-weeks/2462103/The results of a phase 3 trial expands on the efficacy and safety profile of tralokinumab, the first monoclonal antibody (mAb) that targets IL4Rα, blocking signaling of interleukin (IL)-13 and IL-4. Approved in the EU
- Sotyktu Demonstrates Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque PsOhttps://practicaldermatology.com/news/sotyktu-demonstrates-durable-efficacy-and-consistent-safety-for-up-to-three-years-in-moderate-to-severe-plaque-pso/2462066/Bristol Myers Squibb’s